DCTH · CIK 0000872912
What Delcath Systems, Inc. told the SEC could break it.
Delcath's register is a study in single points of failure. Its profitability rests heavily on one product, the HEPZATO KIT for metastatic uveal melanoma, whose active drug, melphalan, comes from a single supplier — the company is in talks with other melphalan ANDA holders but has not yet secured a second source, so a supply interruption would halt its lead product. It also manufactures critical components and assembles HEPZATO and CHEMOSAT at a single ISO 13485 facility in Queensbury, New York, where loss of the site or its certification would limit or stop production. On the demand side it is concentrated as well, with one customer accounting for 15.2% of 2025 revenue and 24.0% of accounts receivable.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- melphalan — single supplier of the active drughigh
Delcath has only one supplier of melphalan, the active drug in its HEPZATO KIT; a supply interruption would halt its lead product. The company is in discussions with other melphalan ANDA holders to diversify but has not yet secured a second source.
“We currently have an agreement with one supplier of melphalan and, with the goal of minimizing the risk of a supply interruption, are in discussions with several melphalan abbreviated NDA holders who have indicated interest in supplying melphalan to us.”
SEC filing →As of 2026
Customer concentration
- largest customer (unnamed) — 15.2% of revenue, 24% of ARmedium
One customer accounted for 15.2% of 2025 revenue and 24.0% of accounts receivable, concentrating both revenue and credit exposure in a single account.
“For the twelve months ended and as of December 31, 2025 % of Revenue % of Accounts Receivable Customer 1 15.2 % 24.0 %”
SEC filing →As of 2026
Geographic concentration
- single Queensbury, NY manufacturing facilitymedium
Delcath manufactures critical components (proprietary filter media, double-balloon catheter) and assembles/packages HEPZATO and CHEMOSAT at a single ISO 13485 facility in Queensbury, New York; loss of that facility or its certification would limit or halt production.
“We manufacture certain critical medical device components, including our proprietary filter media and double balloon catheter and assemble and package CHEMOSAT and HEPZATO at our facility in Queensbury, New York.”
SEC filing →As of 2026
Other disclosures
- single-product dependence on HEPZATOmedium
Delcath's profitability is heavily dependent on a single product, HEPZATO (for metastatic uveal melanoma), so commercialization setbacks or competition would be highly material.
“Our ability to become and remain profitable is heavily dependent on our ability to generate substantial revenue from HEPZATO for the treatment of mUM.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch